Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.31 in the latest trading session, marking a -1.27% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.13%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq lost 0.72%. The company's shares have seen an increase of 13.48% over the last month, surpassing the Medical sector's loss of 2.41% and the S&P 500's gain of 0.78%.The upcoming earnings release of Ginkgo Bioworks Holdings, Inc. will be of great interest ...

Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $10.02, reflecting a -6.36% change from the previous day, underperforming the S&P 500's 0.03% gain [1] - Over the past month, shares of Ginkgo Bioworks have increased by 20.09%, outperforming the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1% [2] - The consensus estimate for revenue is $37 million, representing a 15.62% decrease compared to the same quarter of the previous year [2] Annual Forecast - For the entire year, Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, showing changes of +42.66% and 0%, respectively, compared to the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Ginkgo Bioworks reflect evolving short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Ginkgo Bioworks as 3 (Hold) [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which ranks in the top 36% of all industries according to the Zacks Industry Rank [7] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.85, reflecting a +2.39% change from the previous day, outperforming the S&P 500's daily loss of 0.53% [1] - Over the past month, the company's shares have gained 16.47%, significantly exceeding the Medical sector's gain of 0.09% and the S&P 500's gain of 2.06% [1] Earnings Projections - The upcoming earnings disclosure is projected to show earnings per share (EPS) of -$1.8, which is a 1.1% increase from the same quarter last year [2] - Revenue is anticipated to be $37 million, indicating a 15.62% decrease from the same quarter last year [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, representing year-over-year changes of +42.66% for earnings and 0% for revenue [3] - Recent changes to analyst estimates for Ginkgo Bioworks should be monitored as they reflect evolving short-term business trends [3] Zacks Rank and Industry Performance - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 96, placing it in the top 40% of over 250 industries [6]

Core Insights - MySize, Inc. is evaluating new opportunities to monetize its portfolio of aggregated and anonymized data intelligence assets in a responsible manner [1] Data Intelligence Insights - MySize's platforms have generated large-scale, privacy-compliant insights related to apparel fit trends, sizing mismatches, and product-level performance across brands and retailers, derived exclusively from anonymized and aggregated data [2] - The company is developing a secure Data Intelligence Framework to provide brands, manufacturers, and industry partners with access to insights that support demand planning, inventory optimization, customer trends, product design, and sustainability initiatives [3] Business Model Exploration - MySize is assessing usage-based digital access models, such as data credits, allowing enterprise customers to consume insights in a controlled, transparent, and scalable manner, built with a privacy-first approach and in compliance with data protection regulations like GDPR and CCPA [4] - The initiative remains in an exploratory phase, with no assurance regarding the timing, scope, or potential financial impact of future commercialization [5]

BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT (1:30 p.m. ET). Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events. About Ginkgo Bioworks Ginkgo Bioworks Contacts: INVESTOR CONTACT: [email protected] MEDIA CONTACT: [email protec ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a stock increase of +1.96% to $8.31, outperforming the S&P 500's daily loss of 0.74% [1] - Over the past month, the company's shares have declined by 5.12%, which is worse than the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Upcoming Earnings - The upcoming earnings release is anticipated to show an EPS of -$1.8, reflecting a 1.1% increase from the same quarter last year [2] - Revenue is forecasted at $37 million, indicating a 15.62% decrease compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at -$5.94 per share, representing a 42.66% increase from the previous year [3] - Revenue for the fiscal year is estimated at $173 million, showing a 23.8% decline from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Ginkgo Bioworks are crucial as they reflect the evolving business trends [4] - Positive revisions in estimates are seen as indicators of analysts' confidence in the company's performance and profit potential [4] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Ginkgo Bioworks at 3 (Hold) [6] - The Medical - Biomedical and Genetics industry, which includes Ginkgo Bioworks, holds a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7]

Core Insights - Ginkgo Bioworks has partnered with Carnegie-Mellon University for the POSEIDON program, aimed at early cancer detection and intervention, supported by funding from ARPA-H [1][2] Group 1: Partnership and Project Overview - The partnership involves Ginkgo Bioworks as the Commercial Partner, with the project led by Rebecca Taylor from Carnegie Mellon University [1] - The project aims to develop an innovative orally administered pill with tumor-targeting sensors and a user-friendly at-home cancer screening device [2] Group 2: Technology and Innovation - The pill will utilize synthetic biology and nucleic acid nanotechnology to detect tumor-specific conditions such as low oxygen, acidity, and lactate, which are indicators of cancer [3] - The sensors will release reporters to indicate tumor presence and its tissue of origin, with results collected through urine [3] Group 3: Project Goals and Impact - The dual-function approach aims to provide high precision in detecting hidden tumors, potentially transforming early cancer diagnostics [4] - The project includes a multidisciplinary team from various academic institutions and corporate partners, emphasizing the importance of interdisciplinary collaboration in developing new diagnostics [4]

Core Insights - Thermo Fisher Scientific Inc. has launched two new products, Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), aimed at enhancing plasmid DNA and recombinant protein production using E. coli [1] Product Launch - The new formulations are part of the Gibco™ Bacto™ CD portfolio, designed to simplify and improve the production processes for plasmid DNA and recombinant proteins [1] - The launch responds to the increasing demand for plasmid DNA, which is driven by the growth in gene therapy and mRNA vaccine development [1]

Core Insights - ProteoNic BV's proprietary 2G UNic® technology has been licensed by Ginkgo Bioworks for a project funded by BARDA, aimed at enhancing domestic biomanufacturing of monoclonal antibodies to combat filoviruses like Ebola and Sudan Virus [1][2] Group 1: Project Overview - The project has a total value of up to $22.2 million and involves a collaboration between Ginkgo Bioworks, Advanced BioScience Laboratories, Isolere Bio, NeuImmune, and ProteoNic [2] - The initiative focuses on developing innovative technologies across the entire monoclonal antibody production process, from cell line development to purification, to create a more efficient and cost-effective biomanufacturing solution [2] Group 2: ProteoNic's Role - ProteoNic's contribution centers on its 2G UNic vector and transposon technologies, which are designed to maximize expression and productivity in mammalian systems, thereby enhancing manufacturing efficiency and yield [3] - The technology aims to reduce both time and cost associated with large-scale bioproduction of monoclonal antibodies [3] Group 3: Strategic Importance - The collaboration highlights ProteoNic's expansion into next-generation biologics manufacturing, supporting therapeutic protein production and cell and gene therapy applications [4] - By improving productivity from existing manufacturing infrastructure, ProteoNic's technology aims to bolster biomanufacturing resilience against future global health threats [4]

Core Insights - Ginkgo Bioworks has partnered with Deep Origin on a 4.5-year project funded by ARPA-H to develop a computational platform for drug safety [1][4] - The collaboration, named PREDICTS, aims to enhance pharmacological research through digital integration and clinical trial simulation [1][4] Company Overview - Ginkgo Bioworks specializes in engineering biology and offers customizable R&D solutions, including protein engineering and nucleic acid design [6] - The company utilizes its 'Datapoints' platform to generate large, structured datasets for AI model training, focusing on drug safety and efficacy [2][4] Project Details - The PREDICTS project will leverage Ginkgo's high-throughput capabilities to create detailed models of cellular responses to drug treatments [3][4] - The initiative will include various readouts such as cell type-specific toxicity endpoints and DRUG-seq transcriptomics [2] Strategic Importance - This partnership highlights Ginkgo's commitment to interdisciplinary collaboration and its expertise in generating large datasets for drug development [4] - The collaboration is expected to push the boundaries of multi-omics data generation, transforming drug discovery processes [4]